Efficacy of a new calcium antagonist PN 200-110 (isradipine) in angina pectoris.
Efficacy of a new calcium antagonist PN 200-110 (isradipine) in angina pectoris.
复制标题
新型钙拮抗剂 PN 200-110（伊拉地平）治疗心绞痛的功效。
DOI：
10.1016/0002-9149(87)90091-9
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
P. Pool
中科院分区：
文献类型：
--
作者：
S. Taylor;N. Jackson;J. Allen;P. Pool
心绞痛是检验任何新的钙拮抗剂治疗效果的主要综合征之一。本文报告了一种新型二氢吡啶类钙拮抗剂（PN 200-110 [伊拉地平]）在确诊冠心病患者中的疗效和安全性的中期分析。该研究在3个中心进行;预期96例患者中的50例已在3项单独研究中完成双盲比较期。安慰剂对照研究的初步结果表明，在迄今为止入组的15例患者中，PN 200-110在降低心绞痛发作率和三硝酸甘油消耗方面比安慰剂显著更有效。在21例患者中与硝苯地平和14例患者中与硝酸异山梨酯的剂量反应比较表明，PN 200-110与两种药物具有相似的抗心绞痛疗效特征。在接受PN 200-110的任何患者中，均未观察到任何监测的安全性因素发生显著变化。与硝苯地平相比，其副作用更明显。这些中期结果表明，PN 200-110将被证明是治疗心绞痛的有效和安全的药物。
Angina pectoris is one of the major syndromes against which to test the therapeutic effectiveness of any new calcium antagonist. An interim analysis of the efficacy and safety of a new dihydropyridine calcium antagonist (PN 200-110 [isradipine]) in patients with confirmed coronary artery disease is reported. The study was carried out in 3 centers; 50 patients of an anticipated 96 have completed the double-blind comparative phases in 3 separate studies. Preliminary results from the placebo-controlled study indicate that PN 200-110 was significantly more effective than placebo in reducing the anginal attack rate and glyceryl trinitrate consumption in the 15 patients so far enrolled. Dose-response comparisons against nifedipine in 21 patients and against isosorbide dinitrate in 14 patients demonstrate that PN 200-110 has a similar antianginal efficacy profile to both drugs. No significant change in any of the monitored safety factors was noted in any of the patients taking PN 200-110. The side-effects profile compared favorably with that of nifedipine. These interim results suggest that PN 200-110 will prove to be an effective and safe drug for the treatment of angina pectoris.